




RealRate

PHARMACEUTICAL 2014

Tonix Pharmaceuticals Holding Corp
Rank 150 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Tonix Pharmaceuticals Holding Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tonix Pharmaceuticals Holding Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Tonix Pharmaceuticals Holding Corp is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 92% points.

The company's Economic Capital Ratio, given in the ranking table, is 197%, being 45% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	8,631
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,211
Liabilities, Non-Current	0
Other Assets	60
Other Compr. Net Income	-1.0
Other Expenses	0
Other Liabilities	13
Other Net Income	4.0
Other Revenues	0
Property and Equipment	45
Research and Development	4,650
Selling, General and Administrative Expense	6,238

Output Variable	Value in 1000 USD
Assets	8,736
Liabilities	2,224
Expenses	10,888
Revenues	0
Stockholders Equity	6,512
Net Income	-10,884
Comprehensive Net Income	-10,884
BaseVar	10,926
ECR before LimitedLiability	60%
Economic Capital Ratio	197%